Ropinirole for the treatment of early Parkinson disease

A 12-month experience

K. D. Sethi, C. F. O'Brien, J. P. Hammerstad, C. H. Adler, T. L. Davis, R. L. Taylor, J. Sanchez-Ramos, John M Bertoni, R. A. Hauser

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n = 70; placebo, n = 77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.

Original languageEnglish (US)
Pages (from-to)1211-1216
Number of pages6
JournalArchives of Neurology
Volume55
Issue number9
DOIs
StatePublished - Sep 1 1998

Fingerprint

Levodopa
Placebos
Therapeutics
Parkinson Disease 12
ropinirole
Parkinson's Disease
Parkinson Disease
Ambulatory Care
Outcome Assessment (Health Care)
Placebo
Incidence
Therapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Sethi, K. D., O'Brien, C. F., Hammerstad, J. P., Adler, C. H., Davis, T. L., Taylor, R. L., ... Hauser, R. A. (1998). Ropinirole for the treatment of early Parkinson disease: A 12-month experience. Archives of Neurology, 55(9), 1211-1216. https://doi.org/10.1001/archneur.55.9.1211

Ropinirole for the treatment of early Parkinson disease : A 12-month experience. / Sethi, K. D.; O'Brien, C. F.; Hammerstad, J. P.; Adler, C. H.; Davis, T. L.; Taylor, R. L.; Sanchez-Ramos, J.; Bertoni, John M; Hauser, R. A.

In: Archives of Neurology, Vol. 55, No. 9, 01.09.1998, p. 1211-1216.

Research output: Contribution to journalArticle

Sethi, KD, O'Brien, CF, Hammerstad, JP, Adler, CH, Davis, TL, Taylor, RL, Sanchez-Ramos, J, Bertoni, JM & Hauser, RA 1998, 'Ropinirole for the treatment of early Parkinson disease: A 12-month experience', Archives of Neurology, vol. 55, no. 9, pp. 1211-1216. https://doi.org/10.1001/archneur.55.9.1211
Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL et al. Ropinirole for the treatment of early Parkinson disease: A 12-month experience. Archives of Neurology. 1998 Sep 1;55(9):1211-1216. https://doi.org/10.1001/archneur.55.9.1211
Sethi, K. D. ; O'Brien, C. F. ; Hammerstad, J. P. ; Adler, C. H. ; Davis, T. L. ; Taylor, R. L. ; Sanchez-Ramos, J. ; Bertoni, John M ; Hauser, R. A. / Ropinirole for the treatment of early Parkinson disease : A 12-month experience. In: Archives of Neurology. 1998 ; Vol. 55, No. 9. pp. 1211-1216.
@article{23ee446485f145b182905d427ee6c27f,
title = "Ropinirole for the treatment of early Parkinson disease: A 12-month experience",
abstract = "Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n = 70; placebo, n = 77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8{\%}] of 116) or required the initiation of levodopa therapy (22 [19{\%}] of 116) compared with placebo-treated patients (60 [48{\%}] of 125 patients for insufficient therapeutic response; 57 [45.6{\%}] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0{\%}] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4{\%}] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.",
author = "Sethi, {K. D.} and O'Brien, {C. F.} and Hammerstad, {J. P.} and Adler, {C. H.} and Davis, {T. L.} and Taylor, {R. L.} and J. Sanchez-Ramos and Bertoni, {John M} and Hauser, {R. A.}",
year = "1998",
month = "9",
day = "1",
doi = "10.1001/archneur.55.9.1211",
language = "English (US)",
volume = "55",
pages = "1211--1216",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Ropinirole for the treatment of early Parkinson disease

T2 - A 12-month experience

AU - Sethi, K. D.

AU - O'Brien, C. F.

AU - Hammerstad, J. P.

AU - Adler, C. H.

AU - Davis, T. L.

AU - Taylor, R. L.

AU - Sanchez-Ramos, J.

AU - Bertoni, John M

AU - Hauser, R. A.

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n = 70; placebo, n = 77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.

AB - Objective: To evaluate ropinirole hydrochloride as dopaminergic monotherapy in patients with early Parkinson disease. Design: A 6-month extension of a double-blind, placebo-controlled study. Setting: Ambulatory care at 22 different sites in the United States. Patients: Patients who successfully completed the initial 6-month study could enter the 6-month extension study (ropinirole, n = 70; placebo, n = 77). Intervention: Use of ropinirole or placebo therapy. Main Outcome Measures: The efficacy variables were the number of patients who successfully completed the 12-month study and did not require supplemental levodopa, the number of patients requiring supplemental levodopa, and the proportion of patients having an insufficient therapeutic response. Results: Significantly fewer ropinirole-treated patients met criteria for insufficient therapeutic response (23 [19.8%] of 116) or required the initiation of levodopa therapy (22 [19%] of 116) compared with placebo-treated patients (60 [48%] of 125 patients for insufficient therapeutic response; 57 [45.6%] of 125 patients for additional levodopa). Significantly more ropinirole-treated patients (51 [44.0%] of 116) successfully completed the 12-month study and did not require supplemental levodopa compared with placebo-treated patients (28 [22.4%] of 125). The incidence of adverse experiences and patient withdrawals was low. Conclusion: Ropinirole was effective and well tolerated as monotherapy for 12 months in patients with early Parkinson disease.

UR - http://www.scopus.com/inward/record.url?scp=0031721302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031721302&partnerID=8YFLogxK

U2 - 10.1001/archneur.55.9.1211

DO - 10.1001/archneur.55.9.1211

M3 - Article

VL - 55

SP - 1211

EP - 1216

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -